HOME >> BIOLOGY >> NEWS
APS President-Elect Carey urges 6.7 percent increase for biomedical research

WASHINGTON -- (March 27, 2007) Hannah V. Carey, Ph.D., president-elect of The American Physiological Society (APS; www.the-aps.org) and a professor at the University of Wisconsin School of Veterinary Medicine, today urged Congress to increase funding for the National Institutes of Health (NIH), the nations largest funding source for biomedical research. A 6.7 percent increase in funding for the next fiscal year will help solve pressing health problems such as obesity, heart disease, diabetes and cancer, Carey told the U.S. House Appropriations Subcommittee on Labor, Health and Human Services, and Education.

Carey expressed appreciation on behalf of the scientific community for doubling the NIH budget between 1998 and 2003. Since then, however, funding for the agency has not kept up with inflation. In fact, the NIH funds fewer than one out of five biomedical research grant applications, meaning that top-tier research is not being funded, Carey said. As a result, some of the best medical and scientific ideas are being left unexplored, and our most talented and creative scientists and our scientific leaders of the future are receiving a message of indifference.

Carey urged Congress to support a 6.7 percent increase for the NIH in each of the next three fiscal years. These increases would get the NIH back on track by restoring losses due to inflation in recent years. She also stressed the importance of NIH-funded training programs for the next generation of scientists and said NIH funds are essential to improving science education at all levels. The NIH also funds programs that provide important opportunities for minority students to become more deeply involved in scientific research.


'"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
27-Mar-2007


Page: 1

Related biology news :

1. Contributing membership in the biomarkers consortium surges to 30 companies and nonprofits
2. AAAS urges US President to sign Embryonic Stem Cell Act
3. Virginia study urges early emphasis on science
4. NIH panel urges more informed approach to multivitamin/mineral use for chronic disease prevention
5. New journal article urges use of animal serum-free media for growing live cells
6. US Surgeon General urges Americans to know their family health history
7. To stem disease, keep cats indoors, stop feeding strays, scientist urges
8. AAAS CEO Alan I. Leshner urges US to continue collecting job data on women workers
9. Study urges caution in contaminant source tracking
10. The CF Foundation urges all states to include newborn screening for cystic fibrosis in test panels
11. New study warns limited carbon market puts 20 percent of tropical forest at risk

Post Your Comments:
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
Cached News: